Friday, February 27, 2009

GlaxoSmithKline Takes $400 million charge for off-label promotion of Wellbutrin

GlaxoSmithKline (GSK) is taking a $400 million charge due to an investigation into drugs it manufactures that were allegedly being promoted for off-label use. One of the drugs, Wellbutrin SR, an antidepressant, was being promoted to treat bipolar disorders, which is not FDA approved. The Colorado U.S. Attorny will continue to investigate this drug, as well as nine of GSK’s best selling drug’s sales practices between 1997 and 2004.

Click here to read the full article, GlaxoSmithKline writes off $400 million for off-label deal

Friday, February 06, 2009

Defense Contractor Pays $4 Million in Overbilled Service Hours

A U.S. defense contractor will pay the government $4 million to settle claims that it over billed for hours worked on maintaining helicopters in Iraq. The qui tam lawsuit was filed on behalf of a former employee who will receive a portion of the settlement, according to provisions of the False Claims Act. The company, L-3 Vertex Aerospace, will continue to provide helicopter maintenance to the U.S. Army.

Click here to read the entire article, “Defense Contractor pays $4 Million to U.S. in Settlement"

Defective Bullet-Proof Vests Costs Companies Millions

The United States will receive $1 million from bullet-proof vest manufacturers Barrday Inc. and two other companies to settle allegations in connection with them knowingly selling defective merchandise. The government alleges the companies knew the vests lost their ballistic capability quickly when exposed to heat and humidity, yet continued to sell them anyway. The U.S has previously settled with four other body armor industry manufacturers for over $46 million.

Click here to read the full article on the selling of defective bullet-proof vests and the price of violating the False Claims Act.

Printer Friendly Page